Education
About Us
Working with TipRanks
Follow Us
Bright Minds Biosciences (TSE:DRUG)
:DRUG
DRUG Stock Chart & Stats
C$119.75
C$0.00(0.00%)
At close: 4:00 PM EST
C$119.75
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$33.01 - C$170.00
Previous CloseN/A
Volume70.00
Average Volume (3M)451.00
Market Cap
C$1.01B
Enterprise ValueC$522.10M
Total Cash (Recent Filing)C$82.91M
Total Debt (Recent Filing)C$125.78K
Price to Earnings (P/E)―
Beta29.73
Next Earnings
Feb 18, 2026EPS Estimate
-1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding7,787,161
10 Day Avg. Volume620
30 Day Avg. Volume451
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.07
Price to Sales (P/S)0.00
P/FCF Ratio-66.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$162.28Price Target Upside35.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 2 results reported large reductions in absence seizures and lower total seizure burden on 24-hour EEG in a highly treatment-resistant population, supporting potential effectiveness in difficult-to-treat epilepsy.
Clinical Readout As Value InflectionTop-line data from the Phase 2 BREAKTHROUGH trial represents a potential major value inflection point that could materially change investor perception if efficacy and safety signals are confirmed.
Pipeline Expansion And Strategic PositioningInitiation of a Phase 2a study in Prader-Willi Syndrome alongside development of a next-generation 5-HT2C candidate signals a strategic move to broaden clinical reach beyond seizure disorders and address additional high-need indications.
Bears Say
Competitive LandscapeAnalyst points out the drug trails an established competitor in the same developmental class, which could limit market share even if clinical benefits are demonstrated.
Financing And Dilution RiskAnalyst cautions that planned future equity raises could dilute existing shareholders and weigh on valuation if financing conditions are unfavorable.
Long-term Safety UncertaintyAnalyst flags that long-term safety remains uncertain and that more detailed safety data will be required to fully assess tolerability, which could slow uptake and increase regulatory scrutiny.
Bright Minds Biosciences News
DRUG FAQ
What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was C$33.01 and its highest was C$170.00 in the past 12 months.
What is Bright Minds Biosciences’s market cap?
Bright Minds Biosciences’s market cap is C$1.01B.
When is Bright Minds Biosciences’s upcoming earnings report date?
Bright Minds Biosciences’s upcoming earnings report date is Feb 18, 2026 which is in 39 days.
How were Bright Minds Biosciences’s earnings last quarter?
Bright Minds Biosciences released its earnings results on Dec 24, 2025. The company reported -C$0.61 earnings per share for the quarter, beating the consensus estimate of -C$0.784 by C$0.174.
Is Bright Minds Biosciences overvalued?
According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued.
Does Bright Minds Biosciences pay dividends?
Bright Minds Biosciences does not currently pay dividends.
What is Bright Minds Biosciences’s EPS estimate?
Bright Minds Biosciences’s EPS estimate is -1.29.
How many shares outstanding does Bright Minds Biosciences have?
Bright Minds Biosciences has 7,787,161 shares outstanding.
What happened to Bright Minds Biosciences’s price movement after its last earnings report?
Bright Minds Biosciences reported an EPS of -C$0.61 in its last earnings report, beating expectations of -C$0.784. Following the earnings report the stock price went up 2.111%.
Which hedge fund is a major shareholder of Bright Minds Biosciences?
Currently, no hedge funds are holding shares in TSE:DRUG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bright Minds Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$162.28 (35.52% Upside)
C$162.28 (35.52% Upside)
Blogger Sentiment
Bullish
TSE:DRUG Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
―
20 days / 200 days
Momentum
145.60%
12-Months-Change
Fundamentals
Return on Equity
-30.79%
Trailing 12-Months
Asset Growth
736.23%
Trailing 12-Months
Company Description
Bright Minds Biosciences
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
DRUG Stock 12 Month Forecast
Average Price Target
C$162.28
▲(35.52% Upside)
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
NervGen Pharma
―
Eupraxia Pharmaceuticals
―
Options Prices
Currently, No data available
---